The SimpleMix study with biphasic insulin aspart 30: a randomized controlled trial investigating patient-driven titration versus investigator-driven titration

What Was Tested

This randomized controlled trial paper looks at Insulin Aspart and NPH Insulin (isophane).

Who Took Part

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

Patients with type 2 diabetes were randomized into either patient-driven or investigator-driven BIAsp 30 titration groups.

How the Study Was Run

In design terms this was a randomized, open-label, multicenter and parallel-group study.

Because people in this Insulin Aspart study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Nothing was hidden in this open-label Insulin Aspart study: the participants and staff both knew the treatment.

More than one site took part, so the participants came from several places.

The Insulin Aspart group and the comparison group ran side by side rather than switching.

SimpleMix was a 20 week, open-label, randomized, two-armed, parallel-group, multicenter study in five countries (Argentina, China, India, Poland, and the UK).

What Was Measured

The subject headings attached to it are Biphasic Insulins, Blood Glucose, Blood Glucose Self-Monitoring, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Hypoglycemic Agents and Insulin Aspart.

The authors tagged it with the keywords Biphasic insulin aspart 30, HbA1c and Titration.

What This Means in Plain Language

The paper is a randomized, open-label and multicenter study of Insulin Aspart and NPH Insulin (isophane).

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2014 (Current medical research and opinion), a journal based in England.

More context: the Insulin Aspart compound page and the NPH Insulin (isophane) compound page.